Xia Yu (actor)
Tracked across 1 events · 6 articles · First seen Jul 20, 2026 · Last active Sep 13, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Akeso announced that a pre-specified interim analysis of overall survival (OS) in the Phase III HARMONi-2 (AK112-303) trial, assessed by the Independent Data Monitoring Committee, met the key secondary OS endpoint. Ivonescimab, Akeso's first-in-class PD-1/VEGF…
Impact: Xia Yu (actor), Akeso's Founder, Chairwoman, President and CEO, publicly framed the OS results as reinforcing ivonescimab's clinical value and broader solid-tumor potential.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Xia Yu (actor) live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard